A recalled generic blood thinner has drawn national attention. But the U.S. Food and Drug Administration says the problem is not expected to lead to serious health harm.<\/p>\n
The update came after the FDA reviewed certain recalled generic dabigatran etexilate products, The Healthy<\/a> reported.<\/p>\n What happened?<\/p>\n Major Pharmaceuticals distributed the affected medication nationwide, and the July 17 recall covered two strengths of generic dabigatran etexilate made by New Jersey-based Ascend Laboratories.<\/p>\n The recalled items included 5,460 bottles and were a 150-milligram 60-count carton and 75-milligram cartons in 30-count and 60-count sizes. Testing at the 12-month storage mark found “degradation” and impurity levels outside the product’s specifications.<\/p>\n Each recalled package carries lot number 25141583 and an expiration date of April 30, 2027. The FDA categorized the action as a Class III recall on August 5, which is the agency’s lowest risk level.<\/p>\n The product failed to meet quality requirements, but the agency doesn’t expect it to cause serious health effects for most people who take it.<\/p>\n Why does it matter?<\/p>\n Blood thinners are not casual, over-the-counter medications. They are prescribed to prevent dangerous blood clots and must be taken exactly as directed by a healthcare professional.<\/p>\n Even when a recall is labeled low risk, it can confuse for patients who rely on a medication every day. Some people may worry they should stop taking it right away, while others may not realize their bottle is part of the affected lot, so consulting a pharmacist or physician is always the best advice in these moments.<\/p>\n Not every recall signals an emergency. The FDA’s classification system helps patients and providers gauge how serious a problem is, and in this case, the agency’s review points to a quality issue rather than an immediate threat of serious harm.<\/p>\n Because anticoagulants can raise the risk of excessive bleeding, any question involving a blood thinner deserves careful, medically guided handling.<\/p>\n What can I do?<\/p>\n If you take generic dabigatran etexilate, check your packaging first. Look for lot number 25141583 and the April 30, 2027, expiration date on 150-milligram 60-count cartons or 75-milligram 30-count and 60-count cartons.<\/p>\n A pharmacist or healthcare provider can confirm if a replacement is needed, so reach out if your package matches the recalled lot and expiration date. Getting guidance early can also help prevent any gap in treatment.<\/p>\n Don’t change your medication on your own unless a qualified clinician tells you to do so. Stopping a blood thinner without guidance carries its own risks, especially for people taking it to reduce the chance of stroke or clotting complications.<\/p>\n Keep prescription packaging until the medication is finished, check official recall notices for drugs you use, and ask a pharmacist if anything is unclear.<\/p>\n The FDA’s message offers some reassurance: this is “a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.”<\/p>\n Get TCD’s free newsletters<\/a> for easy tips, smart advice, and a chance to earn $5,000 toward home upgrades. To see more stories like this one, change your Google preferences here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"A recalled generic blood thinner has drawn national attention. But the U.S. Food and Drug Administration says the…\n","protected":false},"author":2,"featured_media":1143262,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4315],"tags":[310865,310866,300937,25096,105,173371,200903,4326,310864,16,15],"class_list":["post-1143261","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-blood-thinner","tag-dabigatran-etexilate","tag-expiration-date","tag-food-and-drug-administration","tag-health","tag-lot-number","tag-major-pharmaceuticals","tag-medication","tag-recalled-items","tag-uk","tag-united-kingdom"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/117078232201666363","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1143261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=1143261"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1143261\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/1143262"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=1143261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=1143261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=1143261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}